Two Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Two Sigma Investments LP grew its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 18.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 212,586 shares of the company's stock after purchasing an additional 33,346 shares during the quarter. Two Sigma Investments LP owned about 0.31% of Replimune Group worth $2,574,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its stake in Replimune Group by 42.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 778,163 shares of the company's stock valued at $9,425,000 after buying an additional 232,822 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Replimune Group by 108.9% during the fourth quarter. Nuveen Asset Management LLC now owns 667,634 shares of the company's stock valued at $8,085,000 after acquiring an additional 347,993 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of Replimune Group during the fourth quarter worth approximately $543,000. Tower Research Capital LLC TRC raised its position in shares of Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after purchasing an additional 5,922 shares during the period. Finally, Swiss National Bank lifted its holdings in shares of Replimune Group by 57.4% in the 4th quarter. Swiss National Bank now owns 103,700 shares of the company's stock worth $1,256,000 after purchasing an additional 37,800 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on REPL. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Piper Sandler lifted their price objective on shares of Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a report on Monday. Finally, HC Wainwright boosted their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $19.75.

Replimune Group Stock Performance

Shares of REPL stock traded up $0.06 during trading on Wednesday, hitting $9.69. The company's stock had a trading volume of 1,033,156 shares, compared to its average volume of 947,504. Replimune Group, Inc. has a 52 week low of $4.93 and a 52 week high of $17.00. The company has a market cap of $746.97 million, a PE ratio of -3.16 and a beta of 0.68. The business has a fifty day moving average of $8.34 and a 200-day moving average of $11.05. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period last year, the firm posted ($0.25) EPS. As a group, research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insider Buying and Selling

In other Replimune Group news, CEO Sushil Patel sold 25,105 shares of the firm's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $202,346.30. Following the completion of the sale, the chief executive officer now directly owns 343,576 shares of the company's stock, valued at $2,769,222.56. This trade represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Christopher Sarchi sold 3,749 shares of Replimune Group stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $30,179.45. Following the completion of the sale, the insider now directly owns 128,296 shares of the company's stock, valued at approximately $1,032,782.80. This trade represents a 2.84% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 74,907 shares of company stock valued at $603,655. 8.80% of the stock is owned by company insiders.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.